Our new design is here! Clearer, more modern, more international. With our new design and visual language we have achieved a strong visual alignment with the corporate identity of Revvity, Inc. At the same time, we harmonized the visual appearance of the Euroimmun and IDS brands creating a new modernized look which visually reflects our shared identity and growing collaboration. But what really counts remains the same: our […]
Currently, dengue fever poses the greatest challenge in terms of arbovirus infections. With over 14 million cases reported worldwide in 2024, this is the largest ever recorded epidemic of vector-borne viral diseases [1]. In Europe, 304 autochthonous cases were registered in the same year, representing a significant increase compared to 130 cases in 2023 and
With passion for rheumatology! The evaluation of the inflammatory status is crucial for the assessment of disease activity and therapy response in systemic autoimmune rheumatic diseases such as rheumatoid arthritis, systemic sclerosis, psoriasis arthritis or microscopic polyangiitis. A promising new biomarker in this context is the increasingly important inflammation parameter circulating calprotectin (cCALP). Calprotectin in
Vector-borne diseases such as dengue, chikungunya, Zika and West Nile fever account for more than 17% of all infectious diseases worldwide [1]. According to the World Health Organization (WHO), over 5.6 billion people live in areas at risk of arboviral infections – that’s more than half of the global population [2]. With over 35 years
Anyone who has got a pet rat at home knows how intelligent and adaptable these animals are. And they are becoming increasingly popular as pets. However, as with all animals in human care, there is a risk of them transmitting pathogens, such as hantaviruses, to humans. Hantaviruses, which occur worldwide, belong to the group of
The integration of Immunodiagnostic Systems (IDS) products into the Euroimmun portfolio has created a unique and broad menu of speciality testing solutions. Our combined chemiluminescence immunoassay (ChLIA) range now spans more than 200 analytes from six diagnostic areas: endocrinology, autoimmunity, infectious diseases, allergy, Alzheimer’s disease and therapeutic drug monitoring. ChLIAs from multiple diagnostic areas can
